Novo Nordisk Investor Presentation - First Nine Months of 2016
Investor presentation
First nine months of 2016
Slide 93
NovoThirteen®, a recombinant FXIII, provides efficacious
and safe haemostatic coverage
Example from NovoThirteenⓇ
promotional campaign¹
purely because he's
Manny Sandow has factor Xl congenital defiuency, Michigan, USA
one in a million
NovoThirteenⓇ properties and launch
performance
Indication:
.
Long term prophylactic treatment of bleeding in adult and
paediatric patients with congenital factor XIII A-subunit
deficiency
Key product characteristics:
• NovoThirteenⓇ is the only recombinant product for
prophylaxis
• NovoThirteenⓇ is well tolerated and has low volume dosing
NovoThirteenⓇ effectively prevents bleeds and provides a
convenient once-monthly regimen
•
Launch status:
•
NovoThirteen® is approved in Australia, Bahrain, Brazil,
Canada, Colombia, EU, Iceland, Israel, Japan, Kuwait,
Oman, Qatar, Saudi Arabia, Switzerland, and the US
1 Picture is not intended for promotional purposes
changing
diabetes®
Source: European Medicines Agency, summary of opinion (post-authorisation) 23
January 2014. NovoThirteenⓇ Summary of product characteristics.
novo nordiskView entire presentation